| 產(chǎn)品編號(hào) | bs-5424R-Gold |
| 英文名稱(chēng)1 | Rabbit Anti-MAP3K7IP3/Gold Conjugated antibody |
| 中文名稱(chēng) | 膠體金標(biāo)記的NFKB激活蛋白1抗體 |
| 別 名 | MAP3K7IP 3; Mitogen activated protein kinase kinase kinase 7 interacting protein 3; Mitogen-activated protein kinase kinase kinase 7-interacting protein 3; NAP1; NF kappa B activating protein 1; NF-kappa-B-activating protein 1; NFkB activating protein 1; TAB-3; TAB3; TAB3_HUMAN; TAK1 binding protein 3; TAK1-binding protein 3; TGF-beta-activated kinase 1 and MAP3K7-binding protein 3; TGF-beta-activated kinase 1-binding protein 3. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul（10nm 15nm 35nm） |
| 研究領(lǐng)域 | 細(xì)胞生物 免疫學(xué) 染色質(zhì)和核信號(hào) 信號(hào)轉(zhuǎn)導(dǎo) 激酶和磷酸酶 表觀遺傳學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 79kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human MAP3K7IP3 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: The product of this gene functions in the NF-kappaB signal transduction pathway. The encoded protein, and the similar and functionally redundant protein MAP3K7IP2/TAB2, forms a ternary complex with the protein kinase MAP3K7/TAK1 and either TRAF2 or TRAF6 in response to stimulation with the pro-inflammatory cytokines TNF or IL-1. Subsequent MAP3K7/TAK1 kinase activity triggers a signaling cascade leading to activation of the NF-kappaB transcription factor. The human genome contains a related pseudogene. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. Function: Adapter linking MAP3K7/TAK1 and TRAF6 or TRAF2. Mediator of MAP3K7 activation, respectively in the IL1 and TNF signaling pathways. Plays a role in activation of NF-kappa-B and AP1 transcription factor. Isoform 2 may be an oncogenic factor. Subunit: Interacts with TAB1, TAB2, MAP3K7, TRAF2 and TRAF6. The minimal TAB3-containing complex (TAB1-MAP3K7-TAB3) appears not to contain TAB2. However, it seems sensible to consider that TAB2 may also join this complex and may act in a cooperative manner with TAB3. Interacts with WDR34 (via the WD domains). Interacts with RBCK1. Binds 'Lys-63'-linked polyubiquitin chains. Interacts with TRIM5. Tissue Specificity: Widely expressed. Constitutively overexpressed in certain tumor tissues. Isoform 1 is a major transcript while isoform 2 is a minor transcript. Post-translational modifications: Ubiquitinated; following IL1 stimulation or TRAF6 overexpression. Phosphorylated at Ser-506 by MAPKAPK2 and MAPKAPK3 following IL1 treatment. Similarity: Contains 1 CUE domain. Contains 1 RanBP2-type zinc finger. Database links: UniProtKB/Swiss-Prot: Q8N5C8.2 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
